Mizuho lowered the firm’s price target on Haemonetics (HAE) to $70 from $90 and keeps an Outperform rating on the shares. The firm says a rebound in Vascade MVP is expected to take at least six months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics Reports Q1 Fiscal 2026 Earnings
- Haemonetics downgraded to Neutral from Overweight at JPMorgan
- Haemonetics: Strong Plasma Performance and Growth in Blood Management Justify Buy Rating Despite Interventional Challenges
- Haemonetics price target lowered to $85 from $105 at BTIG
- Haemonetics’ Strong Financial Performance and Strategic Adjustments Justify Buy Rating Despite Challenges